Bausch + Lomb today announced it received Health Canada approval for its enVista Envy full visual range intraocular lens.
The Health Canada nod is the first regulatory approval of the new lens that offers a full range of vision with dysphotopsia tolerance on the enVista IOL platform.
“enVista Envy is the next step in the dramatic transformation of our IOL portfolio,” said President of Bausch + Lomb’s Global Surgical Unit Luc Bonnefoy. “This first premium IOL on the enVista platform follows the U.S. launch of enVista Aspire late last year. The company plans to launch complementary designs to round out the well-known enVista portfolio in the coming months to better address all patient needs.”
A multicenter, randomized and controlled clinical trial showed excellent long-term outcomes using the enVista Envy IOL in Canada, according to the company. On average, 93% of patients had little to no bothersomeness for dysphotopsia. Additionally, 94% of patients had little to no difficulty viewing close objects while still delivering excellent distance vision spectable-free post-surgery with 4 diopters of continuous visual range, Bausch + Lomb reports.
The intraocular lenses have ActivSync Optic Intelligent Energy Distribution to optimize vision in every lighting condition and ClearPath technology that helps reduce light scattering, according to the company. Low-Cyl toric technology allows the enVista Envy toric lens to simultaneously treat presbyopia and low amounts of astigmatism.
“Today’s cataract patients live vibrant, active lives and have high expectations for vision following surgery,” said Dr. Ada Muzychuk, a doctor at the University of Calgary. “The attributes of enVista Envy, particularly its full range of vision, with very low rates of visual disturbances, position it as an exciting option for patients hoping to live life with greater freedom from glasses and contact lenses. I look forward to offering it in my practice.”
Bausch + Lomb anticipates enVista Envy IOLs to be commercially available in Canada in mid-June. IT is in the process of seeking regulatory approvals for the lens in the U.S. and Europe.
